Clinical Trials Logo

Lung Adenocarcinoma Stage IV clinical trials

View clinical trials related to Lung Adenocarcinoma Stage IV.

Filter by:
  • None
  • Page 1

NCT ID: NCT05503667 Recruiting - EGFR Gene Mutation Clinical Trials

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.

NCT ID: NCT04310943 Completed - Clinical trials for Lung Adenocarcinoma Stage IV

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

The single arm clinical study is to evaluate the efficacy and safety of Tislelizumab combined with Bevacizumab and albumin paclitaxel in the treatment of advanced lung adenocarcinoma. All of the patients were received EGFR-TKI therapy for 1 line and disease progression. The primary endpoint is six months PFS and safety, the seconday endpoint is ORR and one-year OS rate.